Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$56.28 +2.3%	$47.25	$21.02 ▼ $58.40	$4.39B	-0.16	1.03 million shs	2.25 million shs
AXSM Axsome Therapeutics	$102.57 -1.1%	$106.67	$72.21 ▼ $139.13	$5.11B	0.47	669,970 shs	358,053 shs
MESO Mesoblast	$10.75 +1.9%	$11.31	$5.78 ▼ $22.00	$1.35B	2.41	274,883 shs	78,267 shs
PCVX Vaxcyte	$32.88 -0.6%	$33.22	$27.66 ▼ $121.06	$4.27B	1.2	1.45 million shs	1.60 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+2.25%	+2.51%	+22.35%	+31.74%	+145.44%
AXSM Axsome Therapeutics	-1.09%	-0.31%	-1.36%	-13.46%	+33.00%
MESO Mesoblast	+1.90%	-8.04%	-2.01%	-11.23%	+61.90%
PCVX Vaxcyte	-0.63%	-1.56%	+3.62%	-52.66%	-56.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.6334 of 5 stars	3.5	1.0	4.7	1.8	1.7	0.0
AXSM Axsome Therapeutics	4.699 of 5 stars	4.5	2.0	4.5	1.4	4.2	0.6
MESO Mesoblast	2.188 of 5 stars	3.5	3.0	0.0	1.6	0.8	0.6
PCVX Vaxcyte	3.1753 of 5 stars	4.6	2.0	0.0	3.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	46.59% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	68.02% Upside
MESO Mesoblast	3.00	Buy	$18.00	67.44% Upside
PCVX Vaxcyte	3.10	Buy	$136.50	315.15% Upside

Current Analyst Ratings Breakdown

Latest MESO, AXSM, AKRO, and PCVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/7/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$200.00 ➝ $180.00
5/6/2025	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $165.00
5/6/2025	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$160.00 ➝ $162.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
AXSM Axsome Therapeutics	$385.69M	13.09	N/A	N/A	$1.18 per share	86.92
MESO Mesoblast	$5.90M	232.82	N/A	N/A	$4.21 per share	2.55
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.37	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
PCVX Vaxcyte	-$463.93M	-$3.99	N/A	N/A	N/A	N/A	-17.12%	-16.26%	8/5/2025 (Estimated)

Latest MESO, AXSM, AKRO, and PCVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
AXSM Axsome Therapeutics	3.48	2.03	1.96
MESO Mesoblast	0.22	0.96	0.63
PCVX Vaxcyte	N/A	17.70	17.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
AXSM Axsome Therapeutics	81.49%
MESO Mesoblast	1.43%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
AXSM Axsome Therapeutics	22.30%
MESO Mesoblast	18.80%
PCVX Vaxcyte	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
PCVX Vaxcyte	160	129.00 million	125.01 million	Optionable

MESO, AXSM, AKRO, and PCVX Headlines

Recent News About These Companies

GAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

June 21, 2025 | marketbeat.com

Assenagon Asset Management S.A. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 14, 2025 | marketbeat.com

Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Rhumbline Advisers

June 12, 2025 | marketbeat.com

Brokers Offer Predictions for Vaxcyte FY2026 Earnings

June 11, 2025 | marketbeat.com

Vaxcyte: Sentiment Is Pushing The Shares Down

June 10, 2025 | seekingalpha.com

Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Buy" by Analysts

June 5, 2025 | marketbeat.com

103,683 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Universal Beteiligungs und Servicegesellschaft mbH

June 1, 2025 | marketbeat.com

California State Teachers Retirement System Has $8.60 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

June 1, 2025 | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Stock Price Up 5.7% - Should You Buy?

May 30, 2025 | marketbeat.com

Here’s Why Vaxcyte (PCVX) Sold Off in Q1

May 27, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

May 27, 2025 | marketbeat.com

Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?

May 9, 2025 | insidermonkey.com

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | globenewswire.com

Vaxcyte appoints new independent director

May 3, 2025 | uk.investing.com

Vaxcyte Appoints Dr. Olivier Brandicourt to Board

May 1, 2025 | tipranks.com

Vaxcyte, Inc. Appoints Dr. Olivier Brandicourt to Board of Directors to Advance Vaccine Development

May 1, 2025 | quiverquant.comQ

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025 | globenewswire.com

Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now?

April 29, 2025 | insidermonkey.com

Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options

April 23, 2025 | nasdaq.com

Cantor Fitzgerald Initiates Coverage of Vaxcyte (PCVX) with Overweight Recommendation

April 23, 2025 | msn.com

TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)

April 22, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, AXSM, AKRO, and PCVX Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$56.28 +1.24 (+2.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$54.53 -1.75 (-3.12%)

As of 08:00 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics NASDAQ:AXSM

$102.57 -1.13 (-1.09%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$103.24 +0.67 (+0.65%)

As of 08:18 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Mesoblast NASDAQ:MESO

$10.75 +0.20 (+1.90%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$10.76 +0.01 (+0.09%)

As of 06/26/2025 04:04 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Vaxcyte NASDAQ:PCVX

$32.88 -0.21 (-0.63%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$32.98 +0.10 (+0.29%)

As of 04:04 AM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time